0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Viewpoint |

The Economics of Genomic Medicine:  Insights From the IOM Roundtable on Translating Genomic-Based Research for Health

W. Gregory Feero, MD, PhD; Catherine Wicklund, MS, CGC; David L. Veenstra, PharmD, PhD
JAMA. 2013;309(12):1235-1236. doi:10.1001/jama.2013.113.
Text Size: A A A
Published online

Extract

The recent exponential decline in the cost of sequencing human genomes to within an order of magnitude of $1000 has led to increased use of this technology in a variety of research and clinical settings. Examples of clinical sequencing success stories for diagnosing rare conditions are increasingly common and sequencing of tumor samples is being performed in many academic cancer centers to help guide care.1 To date, whole-genome or exome (the protein-coding portions of the genome) sequencing is not a tool being applied to large populations of individuals, but another major decrease in cost may make such testing available to substantial segments of the population. Federally funded exploration of sequencing as an adjunct to routine newborn screening is already underway, and private sector companies are developing expanded carrier screening tests for the purpose of reproductive decision making.2,3 These developments suggest that in the future, genomic sequence data may become a routine component of clinical diagnosis, risk assessment, prevention, and drug selection.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Letters

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 3

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
Jobs
JAMAevidence.com

Care at the Close of Life EDUCATION GUIDES
The Role of Chemotherapy at the End of Life

brightcove.createExperiences();